Biogen (BIIB) Common Equity (2009 - 2026)
Biogen (BIIB) reported Common Equity of $18.85 billion for Q2 2026, up 6.9% from $17.63 billion a year earlier and up 1.1% from the prior quarter.
Powered by 
Analysis
Biogen (BIIB) Common Equity (2009 - 2026) Analysis & Trends
At the end of FY2025, Biogen posted Common Equity of $18.26 billion, up 9.2% from FY2024.
- Common Equity has increased for five consecutive years, with a five-year compound annual growth rate of 11.3% (FY2020 to FY2025).
- By year, Common Equity came in at $16.72 billion in FY2024 (+13.0%), $14.8 billion in FY2023 (+10.5%), $13.39 billion in FY2022 (+22.2%) and $10.96 billion in FY2021 (+2.6%).
- The Q2 2026 figure ranks as the highest quarterly Common Equity in data going back to Q2 2009.
- Year over year, Common Equity has now increased in each of the last 20 quarters, with growth averaging 10.7% over the last eight quarters.
- Over the past five years, the year-over-year growth in Common Equity ranged from 1.3% (Q3 2021) to 22.9% (Q1 2023).
- Per Business Quant data, the three quarters before Q2 2026 came in at $18.65 billion (Q1 2026), $18.26 billion (Q4 2025) and $18.21 billion (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 638.12 Bn | 556.64 Bn | 17.26 Bn | 84.97 Bn |
| 2 | AbbVie | 462.60 Bn | 435.75 Bn | 12.70 Bn | -5.94 Bn |
| 3 | Merck | 358.70 Bn | 313.13 Bn | 12.21 Bn | 41.98 Bn |
| 4 | Novartis Ag | 272.16 Bn | 228.03 Bn | 11.24 Bn | 41.95 Bn |
| 5 | Astrazeneca | 250.36 Bn | 223.92 Bn | 12.86 Bn | 50.37 Bn |
| 6 | Amgen | 227.87 Bn | 183.27 Bn | 7.24 Bn | 11.69 Bn |
| 7 | Gilead Sciences | 184.97 Bn | 159.08 Bn | 6.22 Bn | 11.83 Bn |
| 8 | Pfizer | 162.61 Bn | 109.56 Bn | 10.94 Bn | 85.49 Bn |
| 9 | Vertex Pharmaceuticals | 132.45 Bn | 104.46 Bn | 2.84 Bn | 20.25 Bn |
| 10 | Biogen | 33.37 Bn | 20.03 Bn | 1.96 Bn | 18.85 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 18.85 Bn |
| Mar 31, 2026 | 18.65 Bn |
| Dec 31, 2025 | 18.26 Bn |
| Sep 30, 2025 | 18.21 Bn |
| Jun 30, 2025 | 17.63 Bn |
| Mar 31, 2025 | 16.98 Bn |
| Dec 31, 2024 | 16.72 Bn |
| Sep 30, 2024 | 16.36 Bn |
| Jun 30, 2024 | 15.89 Bn |
| Mar 31, 2024 | 15.21 Bn |
| Dec 31, 2023 | 14.80 Bn |
| Sep 30, 2023 | 14.48 Bn |
| Jun 30, 2023 | 14.46 Bn |
| Mar 31, 2023 | 13.79 Bn |
| Dec 31, 2022 | 13.39 Bn |
| Sep 30, 2022 | 12.77 Bn |
| Jun 30, 2022 | 11.86 Bn |
| Mar 31, 2022 | 11.22 Bn |
| Dec 31, 2021 | 10.96 Bn |
| Sep 30, 2021 | 10.88 Bn |
API Access
Biogen Common Equity API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=common-equity&ticker=BIIB&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "common-equity", "ticker": "BIIB", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=common-equity&ticker=BIIB&period=max&api_key=YOUR_API_KEY");
const data = await res.json();